Product Description
Rivipansel is a synthetic, glycomimetic molecule and pan-selectin antagonist, with potential use in a vaso-occlusive crisis. Upon administration, rivipansel prevents the interaction between leukocytes and the endothelium and may prevent cell activation and adhesion. By preventing selectin-mediated cell adhesion in sickle cell anemia, this agent may inhibit red blood cell-white blood cell interactions, normalize blood flow and reduce inflammation and vascular occlusive pain. GMI-1070 has the strongest antagonistic activity towards E-selectin but a sulfate-binding domain allows for interactions with P- and L-selectins. Selectins, containing lectin- and EGF-like domains, are a family of cell adhesion molecules implicated in inflammatory processes and cancer. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Rivipansel)
Mechanisms of Action: Selectin Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlycoMimetics
Company Location:
Company CEO: Harout Semerjian
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia, Sickle Cell
Phase 1: Healthy Volunteers|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02813798 |
B5201005 | P1 |
Completed |
Kidney Diseases |
2018-02-01 |
52% |
2020-05-12 |
|
NCT02998099 |
PF-06460031 | P1 |
Completed |
Healthy Volunteers |
2017-02-01 |
2020-05-12 |
Primary Endpoints|Treatments |
|
NCT02871570 |
B5201006 | P1 |
Completed |
Healthy Volunteers |
2017-02-01 |
2020-05-12 |
Primary Endpoints|Treatments |
|
NCT02217917 |
B5201007 | P1 |
Completed |
Healthy Volunteers |
2016-04-01 |
2020-05-15 |
Primary Endpoints|Treatments |
|
NCT01941511 |
B5201001 | P1 |
Completed |
Healthy Volunteers |
2014-08-01 |
2020-05-12 |
Primary Endpoints|Treatments |
|
NCT01119833 |
GMI-1070-201 | P2 |
Completed |
Anemia, Sickle Cell |
2012-12-01 |
2020-05-14 |
Primary Endpoints|Treatments |
|
NCT00911495 |
GMI-1070-103 | P2 |
Completed |
Anemia, Sickle Cell |
2010-07-01 |
2020-05-12 |
Primary Endpoints|Treatments |
|
NCT02433158 |
B5201003 | P3 |
Terminated |
Anemia, Sickle Cell |
2019-11-15 |
24% |
2021-02-11 |
Primary Endpoints|Treatments |
NCT02187003 |
B5201002 | P3 |
Completed |
Anemia, Sickle Cell |
2019-05-03 |
10% |
2020-05-07 |